Schering-Plough Opens State-Of-Art Lab In Singapore For Drug Efficacy
This article was originally published in PharmAsia News
Executive SummarySchering-Plough has opened its research facility in Singapore to track the progress of drug effectiveness and allow it to focus on those most likely to succeed. The drug maker opened its new lab at the Biopolis researcher center to use the latest imaging techniques to determine biomarkers to determine whether a drug is working long before attempts are made to market it. Schering-Plough also expects the work in the new lab to determine which drugs to focus on for intended purposes as the firm concentrates on specialized medicine. (Click here for more
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.